0 Recommendations


By Sharonann Lynch | 23 Oct, 2018

[Excuse duplicates]
Please find below a link to MSF’s report-- released at the Union 2018 conference-- with latest pricing and an an analysis of access barriers for drug-resistant TB drugs

Despite some positive updates, access to safe & effective treatment remains poor

www. msfaccess.org/utm5


The report covers topics:

Treatment updates:
WHO issued new recommendations (August 2018) for improved DR-TB treatment include using all-oral regimens, making bedaquiline one of three core drugs to be used in all MDR-TB treatment regimens, and dropping the use of second-line injectable medicines.
These changes more than doubles the number of people for whom bedaquiline-containing regimens are recommended
Although bedaquiline and delamanid can significantly improve treatment outcomes and reduce side effects, they remained inaccessible to nearly 90% of people eligible to receive them in 2017.
Finally, a bit of good news for children with DR-TB: 6 critical paediatric formulations are quality assured through WHO Pre-Qualification or other mechanisms
Drug prices
The report also includes prices of regimens and individual key drugs, such as bdeaquiline, delamanid, clofazamine and linezolid.
Prices have decreased for some key DR-TB drugs. Over the past six years, GDF prices for conventional DR-TB regimens (those recommended by WHO until the latest August 2018 announcement) significantly dropped – by up to 200% for some regimens
However, high prices include J&J’s price of six months of bedaquiline which US$400 (US$67/month) for all countries procuring through GDF.
The estimated price of longer individualized treatment regimens could now reach more than US$2,000 for people who need at least 18 months of bedaquiline, which would represent a 50% price increase over previous standard treatment.
Otsuka keeps its GDF price high at US$1,700 of a six-month treatment (US$283 per month)
The price for people needing both bedaquiline and delamanid for as long as 20 months, the price increase could reach 500%, with a treatment regimen priced at around $9,000.
The report’s supplement includes more information on pricing, registration, sources, dosing, and paeds formulations. It can be found here: https://msfaccess.org/sites/default/files/2018-10/TB_Supplement_UTM_ENG_2018.pdf
Threats to DR-TB treatment scale-up
The Global Fund ‘procurement cliff’: We provide an analysis of the shift from internationally-supported procurement (with multiple suppliers and competitive volume-driven prices) to national purchase of TB drugs and diagnostics and related risks to QUALITY, AFFORDABILITY, and SUPPLY
Lack of national registration of key DR-TB drugs remains a problem, which will be acerbated to the switch to national procurement, given that many countries provide a blanket waiver to commodities procured with Global Fund support.
Should you have questions for our subject-matter experts, including Christophe Perrin the drug-related issues, please write to .


This Community is Archived.

This community is no longer active as of December 2018. Thanks to those who posted here and made this information available to others visiting the site.